Molecular glue degraders: moving beyond IMiDs

The molecular glue degrader field is evolving from tinkering with serendipitously discovered IMiDs to systematic discovery of compounds that can access new protein targets and E3 ligases.

In the eight years since the discovery that Celgene’s immunomodulatory imide drugs (IMiDs) degrade oncogenic transcription factors by “gluing” them to E3 ubiquitin ligases, over a dozen biotechs have cropped up to develop molecular glue degraders, mostly for cancer...